Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

In-Depth Molecular Profiling of Multiple Myeloma in African Americans

Conference Correspondent  - Conference Correspondent, ASH

The Multiple Myeloma Research Foundation (MMRF) is supporting an intensive and comprehensive longitudinal study (CoMMpass) designed to understand how in-depth clinical and molecular profiling can best be used in the context of therapy for multiple myeloma (MM). The patient population in this ongoing study is comprised of self-identified 93 African Americans (AAs) and 377 European Americans (EAs).

A preliminary comparison analysis of CoMMpass data demonstrated overall that there was no statistical difference (P = .5973) in the nonsilent mutation burden between the 2 patient groups—AAs (μ = 63.9 mutations/patient) versus EAs (μ = 73.7 mutations/patient). However, researchers observed that TP53 mutations were more common in EAs 5.6% (21/377) compared with AAs 2.1% (2/93). The analysis also revealed a novel mutation (PTCHD3) with 6% occurrence in AAs compared with only 0.04% in EAs. Several additional genes with higher mutation frequencies in tumors from AA patients were identified, including ANKRD26, BCL7A, and BRWD3. Conversely, the analysis demonstrated a lower frequency of 14q32 translocations in tumors from AA patients (10%) compared with tumors from EA patients (37%).

Data from this comprehensive diverse multi-institutional longitudinal study have allowed researchers to study population differences among MM patients in an unprecedented manner. Identification of potential differences in the genomic and molecular landscape of MM may help the oncology treatment community to further understand the incidence and outcomes among patients from AA versus EA populations.

Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: December 5, 2017